Posted by Michael Wonder on 18 Jul 2018
Remarks from FDA Commissioner as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan
18 July 2018 - Our ability to build a market for safe, effective biosimilar products is key for patients and our nation’s health care system.
It’s a key to promoting access and reducing health care costs. And it’s a key to advancing public health.
But I’m worried that the market for these products still isn’t established. The ability for these products to penetrate clinical practice, and gain acceptance, is still not firm.
